Copyright
©The Author(s) 2023.
World J Clin Cases. Dec 16, 2023; 11(35): 8300-8309
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8300
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8300
Table 1 Baseline data of patients in the different treatment groups
Project | GTG | ITG | t value | P value |
Male:Female | 60:40 | 61:39 | 0.021 | 0.885 |
Age (yr) | 33.15 ± 9.91 | 34.42 ± 10.04 | -0.901 | 0.369 |
DBP (mmHg) | 93.05 ± 6.98 | 93.03 ± 7.73 | 0.019 | 0.985 |
SBP (mmHg) | 140.60 ± 9.94 | 141.40 ± 11.17 | -0.535 | 0.593 |
K (mmol/L) | 4.88 ± 0.97 | 4.72 ± 0.96 | 1.149 | 0.252 |
Hb (g/L) | 128.60 ± 14.97 | 129.65 ± 16.29 | -0.472 | 0.638 |
GFR (mL-1min-1∙(1.73∙m2)-1) | 55.36 ± 3.34 | 54.70 ± 3.27 | 1.405 | 0.162 |
ALT (U/L) | 36.53 ± 3.20 | 37.12 ± 3.30 | -1.279 | 0.203 |
T-CHO (mmol/L) | 5.59 ± 0.99 | 5.55 ± 0.99 | 0.321 | 0.748 |
Glu (mmol/L) | 5.19 ± 0.69 | 5.10 ± 0.66 | 0.883 | 0.378 |
BMI (kg/m2) | 23.06 ± 2.51 | 23.29 ± 2.55 | -0.717 | 0.474 |
Alb (g/L) | 22.94 ± 3.20 | 23.11 ± 3.02 | -0.402 | 0.688 |
24-h urinary protein quantification (g) | 4.01 ± 1.43 | 3.86 ± 1.37 | 0.76 | 0.448 |
Scr (μmol/L) | 121.51 ± 14.58 | 122.16 ± 15.29 | -0.311 | 0.756 |
Table 2 Renal function and proteinuria before and after treatment in both groups
Project | Time | GTG | ITG | t value | P value |
24-h urinary protein quantification (g) | Before the treatment | 4.01 ± 1.43 | 3.86 ± 1.37 | 0.597 | 0.551 |
3 mo after treatment | 2.57 ± 0.69a | 2.40 ± 0.91a | 1.192 | 0.236 | |
6 mo after treatment | 1.62 ± 0.67a | 1.54 ± 0.75a | 0.632 | 0.529 | |
9 mo after treatment | 1.09 ± 0.61a | 0.89 ± 0.50a | 1.985 | 0.049 | |
12 mo after treatment | 0.68 ± 0.38a | 0.39 ± 0.42a | 4.062 | < 0.001 | |
Scr (μmol/L) | Before the treatment | 121.51 ± 14.58 | 122.16 ± 15.29 | 0.244 | 0.808 |
3 mo after treatment | 113.02 ± 21.63a | 112.00 ± 24.72a | 0.247 | 0.805 | |
6 mo after treatment | 108.15 ± 35.2 a | 105.99 ± 34.22a | 0.34 | 0.72 | |
9 mo after treatment | 96.81 ± 34.60 a | 82.23 ± 31.41a | 2.454 | 0.016 | |
12 mo after treatment | 80.30 ± 7.45 a | 64.76 ± 18.32 a | 11.053 | < 0.001 |
Table 3 Comparison of efficacy between the two groups (%)
Project | Ineffective | Obvious effect | Effective | Total effective rate |
GTG | 34 | 21 | 45 | 66 |
ITG | 20 | 15 | 65 | 80 |
χ2 | 4.972 | |||
P value | 0.026 |
Table 4 Prognosis of patients in the two groups
Project | GTG | ITG | χ2 | P value |
Renal endpoint | 14 | 7 | ||
Serious infection | 4 | 2 | ||
Serious liver injury | 4 | 2 | ||
Serious complication | 10 | 8 | ||
Incidence of endpoint events | 32% | 19% | 4.448 | 0.035 |
Follow-up time (mo) | 10.11 ± 3.09 | 11.07 ± 2.08 | 2.000 | 0.048 |
Table 5 Occurrence of adverse reactions in the two groups
Project | GTG | ITG | χ2 | P value |
Gastrointestinal reaction | 18 | 22 | 0.50 | 0.480 |
Anemia | 15 | 24 | 2.580 | 0.108 |
Pneumonia | 11 | 18 | 1.976 | 0.160 |
Transaminitis | 13 | 17 | 0.627 | 0.428 |
Leukocytopenia | 13 | 12 | 0.046 | 0.831 |
Diabetes | 11 | 12 | 0.049 | 0.825 |
- Citation: Meng MJ, Hu L, Fan Y, Gao H, Chen HZ, Chen CM, Qi Z, Liu B. Efficacy of prednisone combined with mycophenolate mofetil for immunoglobulin A nephropathy with moderate-to-severe renal dysfunction. World J Clin Cases 2023; 11(35): 8300-8309
- URL: https://www.wjgnet.com/2307-8960/full/v11/i35/8300.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i35.8300